glp 1 medication for sleep apnea Frontiers Lilly's weight-loss drug reduces sleep
Description
Its 2025 revenue amounted to $46.7 billion
Sleep Duration, Sleep Quality and the Risk of Being Obese: Evidence from the Australian Panel Survey. Sleep Medicine , vol
Masouri MM et al
serves on advisory boards of Sanofi Aventis and Merck Sharp & Dohme (all honoraria paid to employer)
3) Use lay language when explaining risks
Effect of long-acting versus short-acting glucagon-like peptide-1 receptor agonists on improving body weight and related metabolic parameters in type 2 diabetes: A head-to-head meta-analysis
